This recognition has stimulated the development of dietary [7,8] and pharmacological [9] strategies to improve glycaemic control in T2DM by slowing gastric emptying–the latter including “short-acting” glucagon-like peptide-1 (GLP-1) agonists [10] and the amylin agonist, pramlintide [11]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.